𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

Startpagina
België
Brussels
𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

An 𝓲𝓷𝓲𝓽𝓲𝓪𝓽𝓲𝓿𝓮 that encourages 𝕋𝔼𝔸𝕄𝕎𝕆ℝ𝕂 towards «science, education and technology».

07/11/2025

MEM 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

29/10/2025

BICARICU-2 RCT / The outcomes.

European Society of Intensive Care Medicine (ESICM)
𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

29/10/2025

ANDROMEDA-SHOCK-2 RCT / The algorithm used

European Society of Intensive Care Medicine (ESICM)
𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

29/10/2025

The 2nd study presented in the main session ➩ population. / The 2nd study presented in the main session ➩ intervention.

European Society of Intensive Care Medicine (ESICM) 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

29/10/2025

Next SESSION ➩ ECHO clinical interpretation.

European Society of Intensive Care Medicine (ESICM)
𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

29/10/2025

Education ➩ ESICM 2025

ISICEM
European Society of Intensive Care Medicine (ESICM) 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

28/10/2025

Sepsis-associated va sepsis-induced AKI
-Definition and epidemiology of SA- AkI

European Society of Intensive Care Medicine (ESICM)
𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ

13/10/2025

E-learning | 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ
---------------------------------
𝙵𝙾𝚁 𝙷𝙴𝙰𝙻𝚃𝙷𝙲𝙰𝚁𝙴 𝙿𝚁𝙾𝚅𝙸𝙳𝙴𝚁𝚂 / 𝙿𝙰𝚁𝙰 𝙿𝚁𝙾𝚅𝙴𝙴𝙳𝙾𝚁𝙴𝚂 𝙳𝙴 𝚂𝙰𝙻𝚄𝙳
𝐏𝐚𝐭𝐢𝐞𝐧𝐭-𝐂𝐞𝐧𝐭𝐞𝐫𝐞𝐝 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐭𝐨 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐒𝐜𝐥𝐞𝐫𝐨𝐬𝐢𝐬 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧: 𝐀 𝐓𝐨𝐨𝐥𝐤𝐢𝐭 𝐟𝐨𝐫 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐏𝐫𝐨𝐯𝐢𝐝𝐞𝐫𝐬 𝐚𝐧𝐝 𝐓𝐡𝐞𝐢𝐫 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬
This toolkit includes practical approaches to guide providers and patients in detecting subtle signs of MS progression and offers comprehensive strategies for developing treatment plans based on current evidence and patient-centered practices.

🚥 𝗦𝘁𝗮𝗿𝘁 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆: https://primeinc.org/online/patient-centered-approaches-navigating-multiple-sclerosis-disease-progression
---------------------------------
✔ 𝗘 -𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴: https://www.inaaqc.org/e-learning

12/10/2025

𝐃𝐚𝐩𝐚𝐠𝐥𝐢𝐟𝐥𝐨𝐳𝐢𝐧𝐚 𝐦á𝐬 𝐫𝐞𝐬𝐭𝐫𝐢𝐜𝐜𝐢ó𝐧 𝐜𝐚𝐥ó𝐫𝐢𝐜𝐚 𝐩𝐚𝐫𝐚 𝐥𝐚 𝐫𝐞𝐦𝐢𝐬𝐢ó𝐧 𝐝𝐞 𝐥𝐚 𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐭𝐢𝐩𝐨 𝟐
En conclusión, el régimen de dapagliflozina más restricción calórica regular logró una tasa mucho mayor de remisión de la diabetes en comparación con la restricción calórica sola en pacientes con sobrepeso u obesidad con DM 2.

( )

► 𝐎𝐫𝐢𝐠𝐢𝐧𝐚𝐥 𝐬𝐨𝐮𝐫𝐜𝐞: Liu Y, Chen Y, Ma J et al, Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial BMJ 2025;388: e081820
► 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘀𝗼𝘂𝗿𝗰𝗲: https://www.inaaqc.org/2025_asobat

Adres

Route De Lennik 804
Brussels

Website

https://www.inaaqc.org/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer 𝙄𝙉𝘼𝘼𝙌𝘾 ᴮᴼ nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.